This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Sore throat antibiotics and rheumatic fever

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Use of antibiotics in sore throat and risk of rheumatic fever:

  • Rheumatic fever was reported only in randomised controlled trials published before 1961, and the authors noted that the incidence has continued to decline in Western societies since then (1)
    • results from these early studies found that antibiotics reduced acute rheumatic fever by more than two-thirds compared with placebo (low-quality evidence)
      • sixteen studies (n=10,101) reported on rheumatic fever within 2 months, finding a significantly higher incidence in people treated with placebo (1.7%) compared with antibiotics (0.7%, risk ratio 0.27, 95% CI 0.12 to 0.60, p=0.0014)

  • a systematic review noted that (2):
    • antibiotics reduced acute rheumatic fever within 2 months when compared to the control group (Peto OR 0.36, 95% CI 0.26 to 0.50; 18 studies, 12,249 participants; moderate‐certainty evidence)

Reference:

  1. NICE (January 2018). Sore throat (acute): antimicrobial prescribing
  2. Spinks A, Glasziou PP, Del Mar CB. Antibiotics for treatment of sore throat in children and adults. Cochrane Database of Systematic Reviews 2021, Issue 12. Art. No.: CD000023. DOI: 10.1002/14651858.CD000023.pub5. Accessed 21 May 2024.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.